You are here

Article Text

Article menu
Download PDFPDF
Acute paediatrics
Impact of antiretroviral protocols on dynamics of AIDS progression markers
  1. S Resino1,
  2. J M Bellón1,
  3. S Sánchez-Ramón1,
  4. D Gurbindo2,
  5. J Ruiz-Contreras3,
  6. J A León4,
  7. J T Ramos3,
  8. M Á Muñóz-Fernández1
  1. 1Department of Immunology, General University Hospital “Gregorio Marañón”, Madrid, Spain
  2. 2Department of Paediatrics, General University Hospital “Gregorio Marañón”
  3. 3Department of Paediatrics, University Hospital “12 de Octubre”, Madrid, Spain
  4. 4Department of Paediatrics, Unit of Paediatric Infectious Diseases, University Hospital “Virgen del Rocío”, Sevilla, Spain
  1. Correspondence to:
    Dr M A Muñoz-Fernández, Departamento de Inmunología, Hospital General Universitario “Gregorio Marañón”, C/ Doctor Esquerdo 46, 28007 Madrid, Spain;
    Mmunoz{at}cbm.uam.es

Abstract

Aims: To assess the “real life” effectiveness of different antiretroviral therapies (ART).

Methods: A retrospective multicentre observational study in 150 HIV-1 vertically infected children on the progression to AIDS (study A), and in 61 HIV-1 infected children on the evolution of the most relevant markers of progression (study B). All children were categorised into four groups: untreated (NT); on monotherapy (MT); on combination therapy (dual-ART); and on potent ART (HAART).

Results: No child in the HAART group progressed to AIDS, whereas 14 children in the NT and seven in the MT groups progressed to AIDS, respectively, the differences being statistically significant. There was a mean increase of 8 units of %CD4+ per year; this was greater in the HAART group than in the other groups. The mean decrease in viral load was 0.65 log10 copies/ml per year; this was greater in the HAART group than in the NT and MT groups. The HAART group had the lowest probability of returning to baseline %CD4+ and viral load.

Conclusion: Potent ART had the greatest protective effect against progression to AIDS in this observational study.

  • HIV-1
  • antiretroviral therapy
  • progression markers
  • ART, antiretroviral therapy
  • CDCP, Centres for Disease Control and Prevention
  • dual-ART, combination therapy
  • HAART, potent antiretroviral therapy
  • MT, monotherapy
  • NRTI, nucleoside analogue HIV-1 reverse transcriptase inhibitor
  • NT, not treated
  • PI, HIV protease inhibitor
  • RR, relative risk
  • VL, viral load

https://doi.org/10.1136/adc.86.2.119

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes